Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Short term Debt (2023 - 2025)

Xeris Biopharma Holdings' Short term Debt history spans 3 years, with the latest figure at $12.0 million for Q1 2025.

  • For the quarter ending Q1 2025, Short term Debt rose 1071.3% year-over-year to $12.0 million, compared with a TTM value of $12.0 million through Mar 2025, up 1071.3%, and an annual FY2024 reading of $15.1 million, changed N/A over the prior year.
  • Short term Debt for Q1 2025 was $12.0 million at Xeris Biopharma Holdings, down from $15.1 million in the prior quarter.
  • The five-year high for Short term Debt was $17.5 million in Q3 2023, with the low at $420000.0 in Q2 2024.
  • Average Short term Debt over 3 years is $11.1 million, with a median of $15.0 million recorded in 2023.
  • Year-over-year, Short term Debt tumbled 97.48% in 2024 and then soared 1071.3% in 2025.
  • Tracing XERS's Short term Debt over 3 years: stood at $17.5 million in 2023, then dropped by 13.79% to $15.1 million in 2024, then decreased by 20.81% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Short term Debt are $12.0 million (Q1 2025), $15.1 million (Q4 2024), and $420000.0 (Q2 2024).